| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Tandutinib hydrochloride
CAS:2438900-70-8
Package:2mg/RMB 121;5mg/RMB 173
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Tandutinib hydrochloride
CAS:2438900-70-8
Purity:95.00% Package:2mg;5mg
|
| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
021-59167510 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:Tandutinib hydrochloride
CAS:2438900-70-8
Purity:>=99% Package:100mg/ RMB1420；50mg/ RMB884；10mM*1mLinDMSO/ RMB972
|
|
| | Tandutinib (hydrochloride) Basic information |
| Product Name: | Tandutinib (hydrochloride) | | Synonyms: | Tandutinib (hydrochloride);1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-, hydrochloride (1:1) | | CAS: | 2438900-70-8 | | MF: | C31H42N6O4.ClH | | MW: | 599.17 | | EINECS: | | | Product Categories: | | | Mol File: | 2438900-70-8.mol |  |
| | Tandutinib (hydrochloride) Chemical Properties |
| form | Solid | | color | White to off-white |
| | Tandutinib (hydrochloride) Usage And Synthesis |
| Uses | Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML)[1][2]. Tandutinib hydrochloride has the ability to cross the blood-brain barrier[3]. | | in vivo | Tandutinib (60 mg/kg; oral gavage; daily; for 35 days; athymic nude mice) treatment causes a statistically significant increase in survival that was extended on average by 20 days[1]. | Animal Model: | Athymic nude mice injected with Ba/F3 cells[1] | | Dosage: | 60 mg/kg | | Administration: | Oral gavage; daily; for 35 days | | Result: | Caused a statistically significant increase in survival that was extended on average by 20 days.
|
| | IC 50 | FLT3: 0.22 μM (IC50); c-Kit: 0.17 μM (IC50); PDGFR: 0.2 μM (IC50) | | References | [1] Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002 Jun;1(5):421-32. DOI:10.1016/s1535-6108(02)00070-3
[2] Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. DOI:10.1182/blood-2003-05-1669
[3] Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4(4):201-12. DOI:10.2174/187231210792928279 |
| | Tandutinib (hydrochloride) Preparation Products And Raw materials |
|